Breaking News on Global Pharmaceutical Technology & Manufacturing

Hot Topics > Lifecycle management

Access’ oral insulin shows preclinical promise

20-Jan-2010 - Access Pharmaceuticals’ insulin diabetes treatment has shown promise in preclinical trials, achieving over 80 per cent oral bioavailability, leading the company to target proof-of-concept studies in humans.

Vaccine market worth $52bn in 2016

18-Jan-2010 - Global vaccine revenues will be $52bn (€36.2bn) in 2016, more than double the total for 2009, driven by new products and indication expansions of established therapies, according to a report.

Lonza to close Riverside API plant

14-Jan-2010 - Lonza will shut down its API plant in Riverside, Pennsylvania, US by the end of the year as part of a plan to cut costs and shift small-molecule production to...

GSK to shift Avodart production to Poland in 2011

11-Jan-2010 - GSK says it will start making its BPH drug Avodart (dutasteride) at its facility in Poznan, Poland when it completes a PLN70m (€17m) capacity upgrade in January next year.

Luitpold buys PharmaForce for generic injectables

07-Jan-2010 - Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.

Next step towards generics, Pfizer teams with Strides

07-Jan-2010 - Pfizer will soon sell more generic pharmaceuticals in the US after its agreement with Indian non-branded drugmaker Strides Arcolab.

News in brief

CyDex awarded additional Captisol patent

06-Jan-2010 - The US PTO has granted CyDex new patent for the production of ultra high-purity modified cyclodextrin.

Ranbaxy sells China JV and changes strategy

05-Jan-2010 - Ranbaxy Laboratories has sold its Chinese JV, Ranbaxy Guangzhou China Limited (RGCL), as part of a new approach to the country’s rapidly expanding drug market.

Merck & Co to buy Avecia Biologics

21-Dec-2009 - US drug major Merck & Co will buy into the UK's contract biologics manufacturing sector with the acquisition of Tees Valley-based Avecia Biologics.

News in brief

India's focus on APIs and generics helped growth in 2009

21-Dec-2009 - The Indian pharmaceutical market was worth $10.8bn (€7.5bn) this year and will more than double in value by 2014 according to a new industry report by Cygnus Business Consulting & Research.

News in brief

Sanofi targets rural India with generics campaign

14-Dec-2009 - Sanofi Aventis plans to launch 15 new generic products in rural India, under its new Prayas marketing initiative being rolled out through its Hoechst brand.

News in brief

Teva and H Lundbeck raided in latest EC antitrust probe

10-Dec-2009 - Officials carried out another set of surprise inspections at pharma companies yesterday, in the latest stage of the European Commission's clampdown on anti-competitive practices.

News in brief

Teva extends Codexis biocatalyst deal

09-Dec-2009 - Teva will continue to use Codexis’ biocatalysis technology for key processing steps in the production of four generic drugs under a revised agreement announced last week.

Ratiopharm race heats up: Sanofi, Teva and Sinopharm in the lead

09-Dec-2009 - Sanofi-Aventis, Teva Pharmaceutical Industries and Sinopharm lead the pack in the race to acquire German generics firm Ratiopharm.

Watson completes Arrow deal, adding generic Lipitor to US portfolio

07-Dec-2009 - Watson Pharmaceuticals gained US rights to market a generic version of Lipitor (atorvastatin) in 2011 with the acquisition of non-branded drugmaker Arrow Group late last week.

Genzyme ships Cerezyme again; Pfizer licenses Protalix’ rival

03-Dec-2009 - Pfizer and Protalix have increased the pressure on Genzyme by signing a new accord to commercialise Uplyso (taliglucerase alfa), a potential rival to its Gaucher’s disease treatment Cerezyme, just days...

Avon gains on US OK for Ranbaxy’s valacyclovir

02-Dec-2009 - Indian API maker Avon Organics’ share price rocketed 10 per cent on the Bombay exchange yesterday after the US launch of a generic herpes treatment by Ranbaxy Laboratories.

Generics hot up: Cipla in talks with Big Pharma; Takeda mulls M&As

01-Dec-2009 - India’s Cipla is in talks with a number of global pharma players, including Pfizer, about potential generics supply deals.

News in brief

Pharma faces tax hike, says PwC

01-Dec-2009 - The Pharma sector’s shift away from blockbusters could result in higher taxes according to PricewaterhouseCoopers (PwC).

News in brief

Servier’s Irish R&D and manufacturing plant opens

24-Nov-2009 - French drugmaker Servier has opened a new €47m manufacturing and R&D facility in Ireland.

Pfizer may join Japanese generics market in 2011

23-Nov-2009 - Just weeks after completing its billion dollar Wyeth takeover, US drug giant Pfizer has floated the idea of entering Japan’s $5.8bn (€3.9bn)-a-year generic drugs market in 2011 in a bid...

BASF talks novel excipients

18-Nov-2009 - The FDA encourages innovation in excipients to develop new drugs or improve approved therapeutics and IPEC is helping to drive acceptance of these novel products, according to BASF.

Influenza: statins may help, but did aspirin misuse hinder in 1918?

02-Nov-2009 - Early-stage CDC research suggests that the anti-inflammatory properties of cholesterol-busting statin drugs can help mitigate the impact of flu infection.

News in brief

Pfizer, GSK and Bayer accept Ecuador’s plan to break patents

29-Oct-2009 - Late last week Ecuador’s government announced plans to sidestep patents on more than 2,000 drugs, enabling them to produced local or imported as “generics”

Valois discusses what patients want from a device

20-Oct-2009 - Patients want nasal delivery devices that are portable, hygienic and can be used discretely, according to a director at Valois who delivered a talk on the company’s side-actuated product at...

Key Industry Events


Access all events listing

Our events, Shows & Conferences...